MPD: Project measures / variables set: Wiltshire4 Bcells_Sel

Project measures / variables set: Wiltshire4 Bcells_Sel

ID, description, units	MPD:52461 Bcells_Sel B cells, percent viability [%] selumetinib study
Measures	• dose [µM]: • control • 0.046 • 0.137 • 1.235 • 11.1 • 100
Data set, strains	Wiltshire4 inbred w/CC7 34 strains sex: m age: 10wks
Procedure	immune cell quantification
Comparison	control group vs. multiple treatment / dosage groups
Ontology mappings	VT:0002458 B cell quantity VT:0010487 response to xenobiotic stimulus trait MA:0000141 spleen MP:0002458 abnormal B cell number MP:0008872 abnormal physiological response to xenobiotic

SIDE-BY-SIDE STRAIN CURVES

ANOVA, Q-Q NORMALITY ASSESSMENT

ANOVA Summary

Factor	DF	Sum of squares	Mean sum of squares	F value	p-value (Pr>F)
dose	5	11164.0764	2232.8153	4.7676	0.0003
strain	33	77575.3958	2350.7696	5.0195	< 0.0001
dose:strain	165	79913.6285	484.325	1.0342	0.3844
Residuals	594	278185.8423	468.3263

Q-Q normality assessment based on residuals

INDIVIDUAL MEASURES

	Project	ID		Treatment	Measure / Variable Description	Panel	Strains tested	Sex	Age
	Wiltshire4	52461	immune cell quantification	selumetinib	B cells, percent viability [%] control Bcells_Sel_ctrl	inbred w/CC7	34	m	10wks
	Wiltshire4	52462	immune cell quantification	selumetinib	B cells, percent viability [%] dose: 0.046 µM Bcells_Sel_A	inbred w/CC7	34	m	10wks
	Wiltshire4	52463	immune cell quantification	selumetinib	B cells, percent viability [%] dose: 0.137 µM Bcells_Sel_B	inbred w/CC7	34	m	10wks
	Wiltshire4	52464	immune cell quantification	selumetinib	B cells, percent viability [%] dose: 1.235 µM Bcells_Sel_C	inbred w/CC7	34	m	10wks
	Wiltshire4	52465	immune cell quantification	selumetinib	B cells, percent viability [%] dose: 11.1 µM Bcells_Sel_D	inbred w/CC7	34	m	10wks
	Wiltshire4	52466	immune cell quantification	selumetinib	B cells, percent viability [%] dose: 100 µM Bcells_Sel_E	inbred w/CC7	34	m	10wks